STERIS (NYSE:STE) Announces Quarterly Earnings Results

STERIS (NYSE:STE) posted its earnings results on Wednesday. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01), Zacks reports. STERIS had a net margin of 8.02% and a return on equity of 13.78%. STERIS updated its FY 2025 guidance to 9.050-9.150 EPS.

STERIS Trading Up 0.7 %

Shares of STE traded up $1.57 during trading hours on Wednesday, hitting $220.97. 887,926 shares of the stock were exchanged, compared to its average volume of 476,648. The firm has a market capitalization of $21.81 billion, a P/E ratio of 50.45 and a beta of 0.84. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. STERIS has a fifty-two week low of $197.82 and a fifty-two week high of $248.24. The business has a 50-day moving average of $212.26 and a 200-day moving average of $224.61.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.03%. The ex-dividend date is Thursday, February 20th. STERIS’s dividend payout ratio is currently 52.05%.

Insider Activity at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the sale, the senior vice president now owns 11,372 shares in the company, valued at $2,471,363.04. The trade was a 12.88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.14% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on STE shares. Piper Sandler upped their price target on shares of STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 target price on shares of STERIS in a report on Monday, November 18th. Stephens reiterated an “overweight” rating and issued a $260.00 price target on shares of STERIS in a research note on Thursday, November 7th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Finally, StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, STERIS has a consensus rating of “Moderate Buy” and an average target price of $263.75.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.